News
MNKD
3.980
+4.46%
0.170
Allogene Therapeutics (ALLO) Moves 16.4% Higher: Will This Strength Last?
Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks · 06/20 13:28
What Is The Ownership Structure Like For MannKind Corporation (NASDAQ:MNKD)?
If you want to know who really controls MannKind Corporation ( NASDAQ:MNKD ), then you'll have to look at the makeup of...
Simply Wall St. · 06/20 11:22
Mannkind to Host Product Theater and Booth at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7
WESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, will showca...
GlobeNewswire · 06/03 14:00
Hot Stocks: DELL jumps on earnings; IOVA, SWTX plunge on clinical data; UTHR sets high
The major U.S. equity averages scored another day of notable gains, continuing a rebound that started midway through the week. The Nasdaq led the charge with a 3% advance, as
Seekingalpha · 05/27 21:33
Liquidia initiated Buy at BofA on upcoming rival to United Therapeutics
Bank of America launched its coverage on Liquidia Corporation (NASDAQ:LQDA) with a Buy rating after the developer of lung disease drug Yutrepia recently suffered a major setback when a rival
Seekingalpha · 05/26 19:28
United Therapeutics (UTHR) Gains on Tyvaso DPI Approval
The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.
Zacks · 05/25 14:16
United Therapeutics win FDA approval for Tyvaso to treat high blood pressure in lungs
The U.S. Food and Drug Administration (FDA) approved United Therapeutics (NASDAQ:UTHR) Tyvaso DPI (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Seekingalpha · 05/24 10:50
MannKind Highlights FDA Approval Of United Therapeutics' Tyvaso DPI, Which Utilizes Technosphere Inhalation Platform
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients
Benzinga · 05/24 10:10
BRIEF-Mannkind's Technosphere Inhalation Platform Utilized In FDA-Approved Tyvaso DPI
reuters.com · 05/24 10:05
MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™
MannKind celebrates that the FDA has approved United Therapeutics’ Tyvaso DPI™ (treprostinil) inhalation powder Tyvaso DPI™ production is underway at MannKind Corporation (Nasdaq: MNKD) in Danbury, Conn. On May 24, 2022, MannKind celebrated that the U.S. F...
GlobeNewswire · 05/24 10:00
BRIEF-FDA Approves Tyvaso Dpi For Treatment Of Pulmonary Arterial Hypertension To Improve Exercise Ability
reuters.com · 05/23 22:05
United Therapeutics, MannKind gain as FDA approve lung disease therapy
Commercial-stage biotech, United Therapeutics (NASDAQ:UTHR) and its partner MannKind (MNKD) are trading sharply higher on Monday after the FDA announced the approval of their lung disease therapy Tyvaso DPI. Accordingly,
Seekingalpha · 05/23 17:57
MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseas...
GlobeNewswire · 05/19 10:00
PTGX, MNKD and AVGO are among after hour movers
Gainers: Protagonist Therapeutics (PTGX) +10%. Marriott International (MAR) +7%. Aurora Innovation (AUR) +6%. MannKind Corporation (MNKD) +5%. Arcimoto (FUV) +5%. Losers: Enanta Pharmaceuticals (ENTA) -15%. Cisco Systems (CSCO) -12%. Limelight Networks (LL...
Seekingalpha · 05/18 21:57
MannKind to acquire insulin delivery device V-Go from Zealand Pharma to bolster diabetes portfolio
MannKind (NASDAQ:MNKD) is acquiring Zealand Pharma's (ZEAL) V-Go wearable insulin delivery device for $10M, plus sales-based milestones and the cost of certain inventory. MannKind intends to strengthen its commitment to provide mealtime
Seekingalpha · 05/17 10:56
MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma
V-Go® acquired by MannKind Corporation MannKind Corporation announced today an agreement to acquired V-Go® insulin delivery device from Zealand Pharma. V-Go is a once-daily insulin delivery device that strengthens MannKind’s commitment to offering innovati...
GlobeNewswire · 05/17 10:06
MannKind Corporation Participating at Upcoming Conferences
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseas...
GlobeNewswire · 05/09 10:00
BRIEF-MannKind Corp Reports 2022 First Quarter Financial Results
reuters.com · 05/05 21:48
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of 0% and 14.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 21:25
MannKind GAAP EPS of -$0.10 in-line, revenue of $11.99M beats by $1.38M
MannKind press release (NASDAQ:MNKD): Q1 GAAP EPS of -$0.10 in-line. Revenue of $11.99M (-31.3% Y/Y) beats by $1.38M. 1Q 2022 Afrezza Net Revenue of $9.8 million; +21% vs. 1Q 2021
Seekingalpha · 05/05 20:03
More
Webull provides a variety of real-time MNKD stock news. You can receive the latest news about Mannkind through multiple platforms. This information may help you make smarter investment decisions.
About MNKD
MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Technosphere is a drug delivery platform that allow the oral inhalation of a range of therapeutics.